(Q42539672)

2 November 2017

title

Phase I study of paclitaxel (taxol) and granulocyte colony stimulating factor (G-CSF) in patients with unresectable malignancy (English)

1 reference

2 November 2017

1 reference

2

Wiernik PH

1 reference

2 November 2017

Einzig AI

1

1 reference

2 November 2017

Wadler S

3

1 reference

2 November 2017

Kaplan J

4

1 reference

2 November 2017

Benson LT

5

1 reference

2 November 2017

Tentoramano L

6

1 reference

2 November 2017

Tan V

7

1 reference

2 November 2017

publication date

1 January 1998

1 reference

Investigational New Drugs

2 November 2017

published in

1 reference

2 November 2017

volume

16

1 reference

2 November 2017

issue

1

1 reference

2 November 2017

page(s)

29-36

1 reference

https://scigraph.springernature.com/pub.10.1023/a:1006004809169

2 November 2017

exact match

0 references

cites work

Taxol stabilizes microtubules in mouse fibroblast cells

1 reference

12 December 2020

European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion

1 reference

12 December 2020

Taxol assembles tubulin in the absence of exogenous guanosine 5'-triphosphate or microtubule-associated proteins

1 reference

12 December 2020

Interactions of taxol, microtubule-associated proteins, and guanine nucleotides in tubulin polymerization.

1 reference

12 December 2020

Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines

1 reference

12 December 2020

Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103.

1 reference

12 December 2020

Paclitaxel: what schedule? What dose?

1 reference

12 December 2020

Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies

1 reference

12 December 2020

Taxol sensitizes human ovarian cancer cells to radiation

1 reference

12 December 2020

Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines.

1 reference

12 December 2020

Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion.

1 reference

12 December 2020

Taxol-induced polymerization of purified tubulin. Mechanism of action

1 reference

12 December 2020

Dose-finding study of paclitaxel (Taxol) plus cisplatin in patients with non-small cell lung cancer

1 reference

12 December 2020

Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer

1 reference

12 December 2020

Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma.

1 reference

12 December 2020

A phase II trial of taxol in metastatic melanoma

1 reference

12 December 2020

Taxol stabilization of microtubules in vitro: dynamics of tubulin addition and loss at opposite microtubule ends.

1 reference

12 December 2020

Taxol binds to polymerized tubulin in vitro

1 reference

12 December 2020

Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting

1 reference

12 December 2020

Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer

1 reference

12 December 2020

Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer

1 reference

12 December 2020

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

12 December 2020

Neurotoxicity of cisplatin and taxol

1 reference

12 December 2020

Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients

1 reference

12 December 2020

A phase II study of taxol in patients with malignant melanoma

1 reference

12 December 2020

Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans

1 reference

12 December 2020

Clinical toxicities encountered with paclitaxel (Taxol).

1 reference

12 December 2020

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

12 December 2020

Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity

1 reference

12 December 2020

Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.

1 reference

12 December 2020

Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results

1 reference

12 December 2020

Current dosage and schedule issues in the development of paclitaxel (Taxol).

1 reference

12 December 2020

Neurotoxicity of Taxol.

1 reference

12 December 2020

Promotion of microtubule assembly in vitro by taxol

1 reference

12 December 2020

Taxol binds to cellular microtubules

1 reference

12 December 2020

Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms

1 reference

12 December 2020

Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1006004809169

1 reference

Dimensions Publication ID

2 November 2017

1035309568

0 references

1 reference